When presenting, the haemoglobin level was 8.1 g/dl, reticulocytes 0.4%, white blood cell count 17.6 × 10 9 cells/l with 4% blast cells, 2% myelocytes, 77% polymorphonuclear leukocytes, 5% band cells, 6% monocytes and 7% lymphocytes. The platelet count was 30 × 10 9 /l. Further laboratory tests revealed a lactate dehydrogenase (LDH) level of 251 U/l (normal < 250 U/l), a serum ferritin level of 4720 mg/l (normal 15-160 mg/l) and a C-reactive protein (CRP) level of 13 mg/dl (<0.5mg/dl).
Further laboratory tests revealed a lactate dehydrogenase (LDH) level of 251 U/l (normal < 250 U/l), a serum ferritin level of 4720 mg/l (normal 15-160 mg/l) and a C-reactive protein (CRP) level of 13 mg/dl (<0.5mg/dl).
Nootherreasonfortheerythemanodosumwasfound.Rheumatoid factor and anti-neutrophil cytoplasmic antibodies (ANCA) were not detectable;complementfactorsC3andC4werenormal.Theanti-streptolysinelevelwas26IU/ml(normal<360IU/ml);theMantouxtuberculin skintest,Lymeserology,Mycoplasma pneumoniae,Chlamydia pneumoniae and trachomatis serology were negative. Chest X-ray and chest computedtomography(CT)scanrevealednosignofpneumoniaorsarcoidosis.Colonoscopydemonstratedblanddiverticulosis,butnosignsof inflammation.Thehistologicalexaminationofmucosabiopsiesdisplayed no inflammatory bowel disease. The bacteriological stool examination was inconspicuous. No malignancy was found in the chest CT scan, the colonoscopy and the abdominal sonography. The lenalidomide therapy wasterminatedabout4yearsbeforetheonsetoftheerythemanodosum, makingacausallinkunlikely.
The bone marrow biopsy from January 2010, which was taken after the onset of the erythema nodosum, showed no disease progression in comparisontothebonemarrowbiopsyfromSeptember2009.TheInternationalPrognosticScoringSystem(IPSS)indicatedanintermediaterisk II.Afterimmunosuppressivetreatmentwithprednisone40mgdaily,the skin lesions and the ankle pain as well as the laboratory inflammatory signsimprovedwithindays.Thetotalwhitebloodcellcountdroppedto a normal value of 9.2 × 10 9 cells/l with 2% blast cells, 1% myelocytes, 70% polymorphonuclear leucocytes, 3% band cells, 5% monocytes and 15%lymphocytes.
Discussion
MDS can be associated with a variety of skin disorders. In general,anearlyrecognitionofcutaneouslesionsinMDSis important because they can precede blood or bone marrow acutetransformation,thuspredictingapoorprognosis.Thisis especiallytrueforspecificskinlesions,whereastheimpactof unspecificlesions,suchaserythemanodosum,isnotyetentirely clear. Erythema nodosum represents an inflammation
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Introduction
Themyelodysplasticsyndrome(MDS)iscausedbyaheterogeneousgroupofmalignantstemcelldisorders.Itischaracterisedbydysplasticandineffectivebloodcellproductionwith possible progression to acute myeloid leukaemia. Different types of skin lesions have been described in patients with MDS,rangingfromspecificlesionsdefinedbythepresenceof malignanthaematopoieticcellsintheskintonon-specificlesions such as infections, vasculitis and neutrophilic dermatoses [1] . Furthermore, multiple autoimmune manifestations areassociatedwithMDS.Theyarethoughttobecausedby abnormalTcellresponsestoantigenpresentationandabnormalBcellandTcellinteractions [2, 3] .However,erythema nodosuminpatientswithMDSisararecondition [4] .
Case Report
InMarch2010,a74-year-oldwomanwasadmittedwithfatigue,painful swelling of the right ankle, and multiple erythematous, edematous subcutaneousnodularskinlesionsattheextensorsidesofthelowerlegsand forearms ( fig. 1 ). Dermatologic examination involving skin biopsy revealederythemanodosum( fig.2 ).X-rayoftherightanklejointshowed soft-tissueswelling,butnosignofchronicinflammation( fig.3) .Arthralgiawithorwithoutarthritisisafrequentlyseensymptomaccompanying erythemanodosum [5] .Duplexsonographyrevealedepifascialoedemaat thelowerlegs.Thesymptomspersistedfor3monthsbeforepresentation inourclinic.
The patient had been diagnosed with transfusion-dependent World HealthOrganisation(WHO)MDSwithdel(5q)syndromeinSeptember 2005.Otheraberrationsormutations(JAK2,FLT3,orNPM1mutation) were not detected. The patient had initially received lenalidomide therapy, which was terminated due to insufficient effectivity after several months.Apartfromintermittenttransfusionsoferythrocyteandthrombocyteconcentrates,thepatientreceivednofurthertreatment. oftheseptaofthesubcutaneousfattissue [6] andisthought to be determined by type IV delayed hypersensitivity responsetonumerousantigens [7] .Thenagain,thebonemarrowfailurecharacterisingMDS,thoughgenerallyassumedto beanintrinsicstemcellmaturationdefect,maybeassociated with T cell-mediated myelosuppression [3, 8] . In MDS, increased percentages of cytotoxic effector T cells and decreased numbers of regulatory T cells can be found [9] . Regulatory T cell numbers and function seem to correlate inverselywithbonemarrowapoptosis,butalsowithlow-risk disease [10] [11] [12] .Approximately20%ofMDSpatientsachieve sustainedredcelltransfusionindependenceafteranti-thymocyte globulin (ATG) infusion therapy [13] . However, the expansionofthenowunrestraineddysplasticclonemayfacilitate leukaemic progression after the loss of MDS-specific cytotoxicTcells.Thisconcern,however,wasnotverifiedina 10-yearfollow-up [14] .Infact,patientsrespondingtoimmunosuppressive treatment had a decreased rate of leukaemic progression [15] .
ErythemaNodosumAssociatedwith MyelodysplasticSyndrome
Thus,althoughingeneraltheonsetoferythemanodosum canbeanindicatorfordiseaseprogressioninmalignancies,in MDSitmightalsoheraldthepossibilityofaneffectiveimmunosuppressive treatment. Disease progression has been describedin2casesoferythemanodosumassociatedwithMDS [4, 16] .However,immunosuppressivetreatmentwasnotonly abletoimprovetheskinlesionsbutalsotodetaintheprogressionofdysplasticchangesandtoimprovethrombocytopenia in 1 case [4] . The 74-year-old woman in the presented case showed no signs of disease progression 1 month after the Then/Langer/Adam/Oduncu onset of the skin lesions, as determined by bone marrow biopsy. Within 7 months after the onset of the erythema nodosum, there were no changes in haemoglobin levels and blastcell,whitebloodcellandplateletcellcounts.Theskin lesions and ankle joint inflammation responded to immunosuppressivetreatmentwithprednisone,suggestingthatthese symptoms might be an immune-mediated complication of MDS. In summary, the onset of erythema nodosum in patients with MDS may be a sign of autoimmune dysfunction andisnotnecessarilyassociatedwithdiseaseprogression.
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